ATP-CGPharm Group is proud to present the completion of the Laboratoire de Thérapie Cellulaire du Diabète (LTCD) at the Centre européen d’étude du Diabète – CeeD (CeeD) on the site of the Hautepierre Hospital in Strasbourg.
CeeD called on ATP-CGPharm Group to design and build the LTCD’s B, C and D class clean rooms, in compliance with current French and European standards and directives: Good Manufacturing Practices (GMP), the French National Authority for Health (HAS), the French Biomedicine Agency (ABM), etc., enabling the production of sterile pancreatic islet bags in a controlled environment.
This project will enable CeeD to transpose its know-how and mastery of the pancreatic islet isolation technique developed in research grade to a clinical level approved by the Agence Nationale de la Sécurité du Médicament (ANSM), and thus improve the quality of life of type 1 diabetic patients (T1DM).
With this in mind, Strasbourg University Hospital, a recognized islet transplantation center, has joined forces with CeeD to create the first pancreatic islet isolation center in the « Grand Est » region, and more specifically in Strasbourg.
What is our role in this type of project?
ATP-CGPharm Group offers its customers a complete engineering service, from feasibility study to qualification/validation, including all phases of design, planning and implementation, site supervision and acceptance. We offer a turnkey service for the support and realization of projects of all sizes, from research or quality control laboratories to complete production plants (premises, installations, equipment).
The ATP-CGPharm Group team is proud to have taken part in this project, which is now nearing completion, and to have contributed to a major breakthrough in the pharmaceutical industry in France and Europe. We look forward to participating in equally exciting projects in the new year 2024 !
We would like to thank CeeD for placing their trust in us, and all our employees and suppliers who took part in the project
